MX2023014784A - Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. - Google Patents

Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.

Info

Publication number
MX2023014784A
MX2023014784A MX2023014784A MX2023014784A MX2023014784A MX 2023014784 A MX2023014784 A MX 2023014784A MX 2023014784 A MX2023014784 A MX 2023014784A MX 2023014784 A MX2023014784 A MX 2023014784A MX 2023014784 A MX2023014784 A MX 2023014784A
Authority
MX
Mexico
Prior art keywords
diaminoheterocyclic
substituted
preparation
pharmaceutical agents
compound derivatives
Prior art date
Application number
MX2023014784A
Other languages
English (en)
Spanish (es)
Inventor
Ryan West
Simon Ward
Soongyu Choi
Samuele Maramai
Ki Seon Baek
Ja Heouk Khoo
Young Whan Park
Grand Darren Le
Penelope Turner
Tristan Reuillon
Original Assignee
Avelos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avelos Therapeutics Inc filed Critical Avelos Therapeutics Inc
Publication of MX2023014784A publication Critical patent/MX2023014784A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2023014784A 2021-06-09 2022-06-09 Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. MX2023014784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108249.0A GB202108249D0 (en) 2021-06-09 2021-06-09 Compounds
PCT/KR2022/008105 WO2022260441A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents

Publications (1)

Publication Number Publication Date
MX2023014784A true MX2023014784A (es) 2024-03-25

Family

ID=76838874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014784A MX2023014784A (es) 2021-06-09 2022-06-09 Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.

Country Status (10)

Country Link
US (1) US12698278B2 (cg-RX-API-DMAC10.html)
EP (1) EP4352049A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024522201A (cg-RX-API-DMAC10.html)
KR (1) KR20240006692A (cg-RX-API-DMAC10.html)
CN (1) CN117529476A (cg-RX-API-DMAC10.html)
AU (1) AU2022291332A1 (cg-RX-API-DMAC10.html)
CA (1) CA3216629A1 (cg-RX-API-DMAC10.html)
GB (1) GB202108249D0 (cg-RX-API-DMAC10.html)
MX (1) MX2023014784A (cg-RX-API-DMAC10.html)
WO (1) WO2022260441A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023397123A1 (en) * 2022-12-12 2025-02-13 Avelos Therapeutics Inc. Substituted heterocyclic compound derivatives and their pharmaceutical use
EP4637751A2 (en) * 2022-12-23 2025-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Foxm1 inhibitors and their use in treating cancers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
US9096584B2 (en) * 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
PE20151412A1 (es) 2012-11-27 2015-10-10 Thomas Helledays Stiftelse For Medicinsk Forskning Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
JP7503054B2 (ja) * 2018-10-16 2024-06-19 ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド Lrrk2の野生型および変異型のアザインドール阻害剤

Also Published As

Publication number Publication date
EP4352049A1 (en) 2024-04-17
CN117529476A (zh) 2024-02-06
KR20240006692A (ko) 2024-01-15
JP2024522201A (ja) 2024-06-11
US20240300936A1 (en) 2024-09-12
US12698278B2 (en) 2026-08-04
CA3216629A1 (en) 2022-12-15
AU2022291332A1 (en) 2023-12-21
GB202108249D0 (en) 2021-07-21
EP4352049A4 (en) 2025-05-21
WO2022260441A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020551305A1 (en) Pharmaceutical Compounds
JOP20230113A1 (ar) مشتقات ثلاثية الكربوكساميد كمثبطات prmt5
WO2025049274A3 (en) Tetracyclic derivatives, compositions and methods thereof
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SA521421205B1 (ar) مشتقات 6-(4-أمينو-3-أوكسا-8-ازاسبيرو[4.5]ديكان-8-يل)-3-(2.3-داي كلورو فينيل)-2-ميثيل بيريميدين-4(3h)-اون والمركبات ذات الصلة مثل مثبطات ptpn11 (shp2) لعلاج السرطان
CR20220062A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
CR20220207A (es) Compuestos terapéuticos y métodos de uso
PH12021552482A1 (en) Compounds targeting prmt5
EP3693369A3 (en) Bromodomain inhibitors
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2023002907A (es) Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2021011081A (es) Derivados de nicorandil.
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
WO2019199667A3 (en) Pladienolide compounds and their use
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2023014589A (es) Compuestos anticancer.
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).